Skip to content

Evaluation of the improvement of symptoms and of the vulva tissue in Lichen Sclerosus in patients with joint treatment of Anti-inflammatory Cream and the application of energy called Radiofrequency

Evaluation of clinical and histopathological improvement of Vulvar Lichen Sclerosus in patients with combined treatment with Topical Corticosteroids and Fractionated Microablative Radiofrequency

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3d3t8zd
Enrollment
Unknown
Registered
2024-01-15
Start date
2021-12-17
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvar Lichen Sclerosus

Interventions

Women divided into 2 groups: case group (20 patients) and control group (20 patients). Patients in the case group will maintain topical treatment with high-potency corticosteroids and will be held 3 s

Sponsors

Universidade Federal Fluminense
Lead Sponsor
Universidade Federal Fluminense
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histopathological diagnosis of vulvar lichen sclerosus being treated with corticosteroids.

Exclusion criteria

Exclusion criteria: HIV positive women, malignant neoplasms, pregnant women, use of systemic immunosuppressants, no desire to participate in the research

Design outcomes

Primary

MeasureTime frame
It is expected to find clinical improvement in Vulvar Lichen Sclerosus using the fractional microablative radiofrequency method based on the verification of p values ??less than 0.05, which will be considered significant for differences between groups or for association between categorical variables.

Secondary

MeasureTime frame
It is expected to find histopathological improvement in Vulvar Lichen Sclerosus using the fractional microablative radiofrequency method based on the verification of p values ??less than 0.05, which will be considered significant for differences between groups or for association between categorical variables.

Countries

Brazil

Contacts

Public ContactRenata Guimarães

Universidade Federal Fluminense

renatadovalg@gmail.com+55-021-26299031

Outcome results

None listed

Source: REBEC (via WHO ICTRP)